TCBPY (TC BioPharm (Holdings)) EBITDA Margin %: 0.00% (As of Dec. 2024)


What is TC BioPharm (Holdings) EBITDA Margin %?

TC BioPharm (Holdings) TCBPY EBITDA Margin % is 0.00% as of Dec. 2024.

EBITDA Margin % is calculated as EBITDA divided by its Revenue. TC BioPharm (Holdings)'s EBITDA for the six months ended in Dec. 2024 was $-9.01 Mil. TC BioPharm (Holdings)'s Revenue for the six months ended in Dec. 2024 was $0.00 Mil. Therefore, TC BioPharm (Holdings)'s EBITDA margin for the quarter that ended in Dec. 2024 was 0.00%.

TC BioPharm (Holdings)  (OTCPK:TCBPY) EBITDA Margin % Explanation

EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.

TC BioPharm (Holdings) EBITDA Margin % Related Terms

TC BioPharm (Holdings) EBITDA Margin % Historical Data

* Premium members only.

The historical data trend for TC BioPharm (Holdings)'s EBITDA Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

TC BioPharm (Holdings) EBITDA Margin % Chart

TC BioPharm (Holdings) Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
EBITDA Margin %
Get a 7-Day Free Trial -265.94 -531.50 116.76 0.00 0.00

TC BioPharm (Holdings) Semi-Annual Data
Dec19 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24
EBITDA Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only -62.70 0.00 0.00 0.00 0.00

TCBPY vs SIGY, CNBX, SYGGF: EBITDA Margin % Comparison

For the Biotechnology subindustry, TC BioPharm (Holdings)'s EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

TC BioPharm (Holdings) EBITDA Margin % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, TC BioPharm (Holdings)'s EBITDA Margin % distribution charts can be found below:

* The bar in red indicates where TC BioPharm (Holdings)'s EBITDA Margin % falls into.


TC BioPharm (Holdings) EBITDA Margin % Calculation

EBITDA margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent.

TC BioPharm (Holdings)'s EBITDA Margin % for the fiscal year that ended in Dec. 2024 is calculated as

EBITDA Margin %=EBITDA (A: Dec. 2024 )/Revenue (A: Dec. 2024 )
=-15.641/0
= %

TC BioPharm (Holdings)'s EBITDA Margin % for the quarter that ended in Dec. 2024 is calculated as

EBITDA Margin %=EBITDA (Q: Dec. 2024 )/Revenue (Q: Dec. 2024 )
=-9.005/0
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBITDA Margin % →
What does a EBITDA Margin % of 0.00% mean?
TC BioPharm (Holdings) (TCBPY) has a EBITDA Margin % of 0.00% as of Dec. 2024. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on TC BioPharm (Holdings) and its competitors.
Is TC BioPharm (Holdings)'s EBITDA Margin % too high?
TC BioPharm (Holdings)'s current EBITDA Margin % is 0.00%.
How does TC BioPharm (Holdings)'s EBITDA Margin % compare to SIGY and CNBX?
TC BioPharm (Holdings)'s EBITDA Margin % of 0.00% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Biotechnology company?
A good EBITDA Margin % depends on the Biotechnology industry context. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on TC BioPharm (Holdings) and its competitors. TC BioPharm (Holdings)'s current EBITDA Margin % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is TC BioPharm (Holdings) stock overvalued right now?
TC BioPharm (Holdings) (TCBPY) has a current EBITDA Margin % of 0.00%. The current EBITDA Margin % is 0.00%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For TC BioPharm (Holdings) (TCBPY), the current EBITDA Margin % is 0.00% as of Dec. 2024. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

TC BioPharm (Holdings) Business Description

Address Maxim 1, 2 Parklands Way, Holytown, Motherwell, Scotland, GBR, ML1 4WR
TC BioPharm (Holdings) PLC is a clinical-stage biopharmaceutical company focused on developing novel immunotherapy products that are based on its proprietary allogeneic gamma delta T (abbreviated as GD-T) cell platform. Harnessing the innate ability of GD-Ts has enabled the company to develop a range of clinical-stage cell therapies designed to combat cancer and viral infection.